Ready-to-use, CE-IVD antibodies for pathology

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Ready-to-use, CE-IVD antibodies for pathology"

Transcription

1 A-1-Antichymotrypsin A-1-Antitrypsin Abcc3 Aberrant Endothelial 4A11 Cell ACTH BSB-25; AH26 Actin 1A4 Actin, Muscle Specific HHF35 Actin, Smooth Muscle BSB-15 (ASM/H12) Adenovirus 20/11 and 2/6; A A Adipophilin / ADRP BSB 91 Afp C3 AldH1A1 EP168 ALK SP144; EP302 Alk/P80 SP8 ALK-1 RBT-ALK1 Alpha Actinin JLN20 Alpha Synuclein BSB-114 Alpha-1-1A88 Antichymotrypsin Alpha-1-Antitrypsin Alpha-Fetoprotein BSB-23; EP209 AMACR / P504S 13H4; RBT-AMACR Amyloid A EP335 Amyloid Beta RBT-A4 Androgen Receptor BSB-4 (AR-D12); F Annexin A1 BSB-95 Apolipoprotein E EP1373Y Arginase-1 EP261 ATRX BSB-108 B7H3/CD276 RBT B7H3 BAP1 BSB-109 Bax E63; BCA-225 Cu-18 B-Cell MB2 Bcl-10 BSB-22 Bcl-2 BSB-5 (BCL2/A4); bcl-2/100 Bcl-2 E17; EP36 Bcl-2 Alpha SP66 Bcl-6 BSB-26; LN22 Bcl-6 EP278; RBT-bcl6 Bcl-X E18; EP94 Beta Catenin EP35; E247 Beta-Catenin 14 Beta-Hcg M94138 Beta-Tubulin III SDL3D10 Bfgf bfgf88 BG8 LewisY F3 Bla-36 A27-42 BOB.1 EP114; SP92 Brachyury RPab BRAF V600E RM8 Brca1 Breast Ca. Ag. Bca-225 CU18 C3d C4d EP273; Ca-125 OC125; Ov185:1 Ca-125 EP48 Ca-15-3 DF3 Ca SLE; C241:5:1:4 LI-Cadherin EP86 Cadherin-6 EP217 Calcitonin SP17; EP92; Caldesmon BSB-19 (CALD-31) Caldesmon E89; EP19 Caldesmon Hmw h-cd Calponin BSB-20; CALP Calponin-1 EP798Y Calretinin 2E7 Calretinin EP1798; SP13; Carbonic Anhydrase 9 EP161 Catenine Delta 1 (P120) Cathepsin D C15 Caveolin-1 EP353 CD10 56C6 CD10 EP195 CD103 / ITGAE EP206 CD105 4G11 CD105 EP274 CD105 / Endoglin CD117 T595 CD117 EP10; YR145 CD117 / C-Kit EP10 CD117 / C-Kit / Scf CD11B M01 CD11B/Itam EPR1344; EP45 CD11C EP157; EP1347Y CD123, IL-3Ra BSB-59 (CD123-D3) CD13 38C12 CD13 EP117; EPR4058 CD134 / OX-40 BSB-90 CD138 B-A38 CD138 EP201 CD14 7 CD14 EP128; EPR3653 CD141 EP175 CD146 EP54 CD15 MMA; BRA4F1 CD15 EP272 CD152 / CTLA-4 BSB 88 CD16 2H7 CD16 EP364 CD163 10D6 CD163 EP324

2 CD16A EP169; SP175 CD19 BSB-97 CD19 EP169 CD1a EP80 CD1A O10 CD2 AB75 CD20 L26; CD20/C23 CD205 EP176 CD207 / Langerin EP349 CD207 / Langerin 12D6 CD21 B2 CD21 EP64; SP186; EP3093 CD22 FPC1 CD227 VU-4H5 CD23 1B12 CD23 EP75; CD25 4C9 CD25 RBT-CD25 CD274 / PD-L1 RBT-PDL1 CD279 / PD-1 NAT-105 CD279 / PD-1 EP239 CD29 JB1a CD3 RBT-CD3; EP41 CD3 (T-Cell) PS1; UCHT1 CD3 Epsilon RBT-CD3e; EP449E CD30 Ber-H2 CD30 (Ki-1Ag) Ber-H2; HRS-4 CD31 1A10; JC/70A CD31 (Pecam-1) 9G11 CD33 RBT-CD33 CD34 QBEnd/10 CD34 EP88 CD35 RLB25 CD35 EP197; SP191 CD38 SPC32 CD38 EP135; SP149 CD4 4B12 CD4 RBT-CD4; EP204 CD41/ ITGA2B EP178 CD43 MT1; DFT-1 CD43 SP55 CD43 & CD45Ra MT1 & MB1 CD44 BSB-12; DF1485 CD45 2B11 & PD7/26 CD45 (Lca) LCA88; LJ27.9; PD7/26/16 & 2B11 CD45R MB1 CD45RA 4KB5 CD45Ra (B Cell) MB1 CD45Rb MEM55 CD45Rc (T Cell) MT2 CD45RO UCHL-1 CD48 EP48 CD5 RBT-CD5; RED1; EP77; EP2952 CD5 4C7 CD53 EP179 CD56 123C3.D5; NKH-1 CD57 BSB-10 (CD57/B8); NK-1 CD6 BSB-54 CD61 2f2 CD61 EP2417Y CD63 NKI/C3 CD63 EP211 CD68 KP-1; BY114; BSB-8 (CD68/G2); CD68/G2; KP1 CD7 LP15 CD7 SP94 CD71 10F11; H68.4; T9 CD74 LN2 CD75 LN-1 CD79A JCB117; 11E 3 CD79A EP82; SP18 CD7d EP132 CD7d LP15 CD8 C8/144B; 1A5; T8 CD8 EP334; SP16 CD8 (C-Term) EP1150Y CD82 EP160 CD9 EPR2949 CD90 EP56 CD95 EP208 CD99 BSB-9 (CD99/B5); HO CD99 EP8; EPR3097Y CDK2 RBT-CDK2 CDK4 EP180 Cdw75 (B Cell) LN1 CDX2 EP25 CDX2 CDX2-88 CEA BSB-13 (CEA31); B M-P; CEA88 CEA C-Erbb-2 SP101; SP3 C-Erbb-2 (Her-2/Neu) CB11 C-Erbb-3 (Her-3) RTJ1/A2 Chromogranin A LK2H10; PHE-5 Claudin-1 Claudin-5 EP224 Clusterin / EP181 Apolipoprotein J c-met / HGFR EP1454Y CMV BM204 c-myc 9 E10 c-myc EP121 Collagen III HWD1.1 Collagen IV CIV22; COL-94

3 COX-2 EP293; SP21; RBT- COX2 Cyclin B1 RBT-B1 Cyclin D1 EP12; RBT14; EPR2241(IHC)-32; Cyclin E1 EP126 Cyclin E2 EP454Y Cytokeratin 34βE12/C51/AE1; CK88 Cytokeratin 10 DEK-10 Cytokeratin 10 EP97 Cytokeratin 13 AE8 Cytokeratin 13 EP69 Cytokeratin 14 LL002 Cytokeratin 14 EP61; EP1612Y Cytokeratin 15 EP14; EPR1614Y Cytokeratin 16 EP27; EP1615Y Cytokeratin 17 BSB-33 Cytokeratin 17 EP98 Cytokeratin 18 DC-10 Cytokeratin 18 EP30 Cytokeratin 19 BSB-34; RCK108 Cytokeratin 19 EP72 Cytokeratin 20 Ks20.8; IT-Ks20.8 Cytokeratin 20 EP23; EPR1622Y; EP23 Cytokeratin 35BH11 35betaH11 Cytokeratin 4 6B10 Cytokeratin 4 EP4 Cytokeratin 5 EP24; EPR1600Y; EP42 Cytokeratin 5 & 14 EP24/ EP61 Cytokeratin 5 & 6 D5/16B4 Cytokeratin 5 & 6 EP24/ EP67; EPR1600Y, EPR1602Y Cytokeratin 5 & 6 & EP24/ EP67/EP111 ERG Cytokeratin 5 & ERG EP24/ EP111 Cytokeratin 6 EP67; EPR1602Y Cytokeratin 7 OV-TL 12/30 Cytokeratin 7 EP16; EPR1619Y Cytokeratin 7 & 8 OV-TL12/30 & C51 Cytokeratin 7 & CDX2 EP16/ EP25 Cytokeratin 8 C51 Cytokeratin 8 EP17 Cytokeratin 8&18 B22.1&B23.1; 5D3 Cytokeratin 8&18 EP17 & EP30 Cytokeratin Cocktail AE1/AE3 Cytokeratin HMW AE3; 34βE12 Cytokeratin LMW CAM5.2; AE1 Cytokeratin Pan C11; Lu-5 Cytokeratin, OSCAR OSCAR Cytokeratin17 E27 Desmin D33; 33 Desmin EP15 Desmoglein-3 BSB-61 Desmoglein-3 EP306 DOG-1 1,1 DOG-1 EP332; RBT-DOG1 Dystrophin 1 Dys1 (Dy4/6D3) Dystrophin 2 Dys2 (Dy8/6C5) E Cadherin EP6 E2F4 EP252 Ebv E-Cadherin 36 E-Cadherin EP6 EGFR 31G7 EGFR EP22; EGFR Phospho EP11 EMA E29; Mc5 EpCam E144; EP155 EpCam Ber-EP4; MOC-31 EBV, LMP-1 CS1-4 Er (Insite) ER88 Er Alpha EPR702 (2) Er-Beta ERCC1 EP219 ERG EPR3864; EP111 Estradiol Estrogen Receptor BSB-1 Estrogen Receptor EP1; RBT11 Estrogen Receptor- EP1 Alpha Factor VIII-Related Ag BGX016A Factor VIII-Related Ag Factor XIIIa E980.1 Factor XIIIa EP292; EP3372 Fascin BSB-36; FCN01 Fibronectin F14 Fli1 Fli-1 G Follicular Dendritic CNA.42 Cell FOXA1 / HNF-3A EP277; FOXO1 EP290 FOXP1 EP137 FOXP3 EP340; FSH BSB-55 FSH Galectin-3 9C4 Gastrin GATA3 L GATA3 EP368 GCDFP-15 23A3 GCDFP-15 EP95 GFAP EP13; GFAP GA-5 GH EP267; GH BSB-99

4 Glepp-1 5C11 Glucagon EP74; Glucagon BSB-111 GLUT1 SPM498 GLUT1 EP141 Glutamine Synthetase GS-6 Glycophorin A GA-R2 (HIR2) Glycophorin A+B HIR2 Glypican-3 1G12; GPC3-88 Granzyme B EP230; Gst Pi H S A HSA/E8 H.Pylori BSB-37 H.Pylori EP279; hcg BSB-38 HE4 EP370 Hemoglobin A EP124; Hep. B Core Ag. Hep-Par1 OCH1E5 HER-2 neu BSB-3 (HER-24) HER-2 neu EP3; RBT-HER2 HER2 neu Phospho EP123 HER-3/c-erbB-3 RBT-HER3 HSV I HSV I 10A3 HSV I & II HSV II hgal / GCET2 EP316 Hgh 54/9 2A2 Hgh HHV-8 13B10 HIF-1alpha EP118 Histone H3 Phospho EP233; HLA-DR LN3 hpl EP241; HPV BSB-66 (SB 24) HPV16 CAMVIR-1 Hsp 70 BRM-22 HSP-27 G3.1 IgA BSB-39 IgA IgD EP173; IgG BSB-40; IgG88 IgG IgG4 BSB-96 IgG4 EP138 IgM BSB-41; IgM88 IgM IMP-3 / 1GF2BP3 EP286 Inhibin Alpha R1 Inhibin Alpha EP378 INI-1 25 inos RBT-iNOS Insulin BSB-42; HB125 Insulin EP125 Islet 1 / ISL1 EP283 J Chain JC88 J-Chain SP105 Kappa Light Chain BSB-58; L1C1; K88 Ki-67 BGX-Ki67; Ki88; BGX-297 Ki-67 EP5; EPR3611 Kras Ksp-Cadherin 4H6/F9 LAG-3 / CD223 EP294 Lambda BSB-16 (Lamb14) Lambda Light Chain EP172; SP147; Laminin LEF-1 EP310 LH BSB-53 LH SP132 Lysozyme EP134; Macrophage HAM-56; LN5 Mammaglobin EP249 Mart-1 / Melan A A103; M2-7C10 Maspin BSB 92 Mast Cell Tryptase AA1 MCM2 RBT-MCM2; SP85; EP40 MCM3 EP202 MCM5 RBT-MCM5 MDM2 BSB-64 MDR MDR88 MDR-1 JSB-1 MDR-1 EP271 Melan-A A103 Melanoma PNL2; KBA.62; HMB45 Melanoma Assoc. Ag NKI/C3 Melanoma: HMB-45, HMB-45, A103 & Mart-1 & Tyrosinase BSB-6 Melanoma Gp100 gp100/d5 Melanosome HMB-45 Mesothelia Cell HBME-1 Mesothelin EP140 Mesothelin 5B2 MITF C5/D5; MiTF/A13 MLH1 G ; ES05 MMP-9 EP127; EP1255Y MSH2 G MSH2 RBT-MSH2; SP46; Red2 MSH6 44; 2D4B5 MSH6 EP49 MUC1 BSB-44 MUC1 EP85; EPR1023 MUC2 BSB-45; CCP58 MUC2 EP187 MUC4 8G7; 1G8

5 MUC4 EP256 MUC5 45M1 MUC5AC CLH2 MUC6 CLH5 MUM1 EP190 Mum1/Irf4 SP114 Muscle Actins Actin 88 Cocktail M. tuberculosis Myelin Basic Protein MBP88 Myelin Basic Protein EP207; Myeloid Sp. Ag BM-3; BM-1 Myeloperoxidase EP151; Myf-4 LO26 MyoD1 EP212 Myogenin F5D Myogenin EP162 Myoglobin BSB-104; MG-1 Myoglobin EP87; Myosin MY-32 Myosin Heavy Chain SMMS.1 Myosin, Smooth BSB-17 (SMM-H24) Muscle Napsin A BSB-112; IP64 Napsin A EP205 N-Cadherin EPR1792Y Nestin EP286 NeuN A60 Neuroblastoma NB84a Neurofilament 2F11; NE-14 Neurofilament EP79 Neutrophil Elastase EP223 Ngf Receptor EP1039Y; EP31 Ngf Receptor BSB-18 NKX2.2 EP336 NKX3.1 EP356 NRAS (Q61R) RBT-NRAS NSE BSB-94; MIG-N3 OCT-2 EP115; EPR542 OCT-4 EP143 OLIG2 EP112 Osteonectin OST1 Osteonectin / SPARC BSB 93 p105 Pana 2B3 p120 (Catenin Delta 1) SP63 p120 Catenin EP66; YE372 p16 (Ink4) G p21 DCS-60.2; 4D10 p27 SX53G8; DCS72 p27 (Kip1) Y236 p34 POH-1 p40 ZR8 p53 DO7; 1801; BP53-12 p53 EP9 p57 Kp10 p63 EP174 Pap A40010 Parafibromin BSB-50 Parathyroid Hormone/ BSB-24 PTH Parvalbumin EP300 Parvovirus R92F6 PAX-2 EP235 PAX-5 ZP007 PAX-5 RBT-PAX5 PAX-6 EP341 PAX-8 ZR-1; EP298 Paxillin EP89; Y113 Pcna PC10 Pdcd4 EP102; EPR3432 Pdgf PDGF88 Pdgf PDGFR-B RBT-PDGFRB; Y92 PDX1 EP139 Perforin 5B10 PGP 9.5 BSB-46; 3D9 Placental Lactogen PLAP BSB-47; PL8-F6 PLAP EP194 PMS2 EPR3947; EP51 Pneumocystis jirovecii 3F6 Podoplanin / D2-40d D2-40 Prealbumin EP2929Y Progesterone Receptor BSB-2; 1A6 Progesterone Receptor RBT22; EP2 Progesterone Receptor PR88 (Insite) Prolactin PRL02; BGX031A Prolactin EP193 Prostein / P501S ZR-9 Ps2 Estrogen PS2.1 Psa ErPr8 PSAP PASE/4LJ; B M-NA PSAP EP53 PSMA EP192; SP29 PSP94 / MSMB EP203 PTEN 6H2.1 PTEN RBT-PTEN; SP218 PU.1 EP18 Renal Cell Carcinoma PN-15; RCC-26 Retinoblastoma (Rb) 1F8 S- 100Beta EP32 S-100 4C4.9; 15E2E2 S-100 S-100A1 EP184 S-100A6 EP313 S-100A8 / MRP8 EP90 S-100A9 EP185 S-100P EP186 SALL4 6E3

6 SALL4 EP299 Sarcomeric Actin ZMSA-5 SATB2 EP281 Secretin SMAD4/DPC4 BSB-63 SMAD4/DPC4 RBT-SMAD4 Smoothelin R4A Somatostatin EP130; Somatostatin BSB-113 SOX-10 BSB-62 SOX-10 EP268 SOX-11 CL0142 SOX-2 EP103; SOX-9 EP317 Spectrin RBC2/3D5 Spectrin EP251 Stat5- Alpha (C-Term) E289 STAT6 EP325; Stathmin EP247 Substance P Survivin EP119; EP2880Y SV40 Pab101 Synaptophysin EP158; Synaptophysin Snp88 T.Gondii TAG-72 BSB-21 (Tag72-22); B72.3 Tag-90, Bca B6.2 Tau BSB-115; Tau5; Tau2 T-Bet/TBX-2 EP263 TCL1 EP105 TCR Beta F1 8A3 TdT TdT88 TdT EP266; RBT-TdT; TFE3 EP285 Tfpu.1 EPR3159Y Tgf-Alpha TGF88 Thyroglobulin 2H11/6E1; BSB-49; 2H11 Thyroglobulin EP250 Thyroid Peroxidase EP159 Thyroxine D5 TIA-1 TIA-1; 2G9A10F5 TLE1 1F5 Topo2 Alpha EP1102Y Topoisomerase II EP93; RBT-Topo2a Alpha TRAcP 9C5 Transferrin HT1/ Treponema pallidum Tryptase G3 Tryptase EP259 TSH BSB-56; 5404 TSH EP254; TTF-1 8G7G3/1; BGX-397A Tyrosinase BSB-6; Ty/G5 Uroplakin III EP321; VZF SG1-1, SG1-SG4, NCP-1 & IE-62 VEGF RBT-VEGF; Villin CWWB1; ID2C3 Villin EP163 Vimentin V9; LN6 Vimentin EP21 Vip WT1 6F-H2 Zap-70 2F3.2; ZAP70-C3 Zap-70 EP52; YE291 For more information or to place an order, contact us.

antibodies by application

antibodies by application antibodies by application Higher Affinity Higher Sensitivity Higher Specificity A selection of Over 460 Rabbit and Mouse Monoclonal For Use in Clinical and Research Applications Bio SB s RBT & MMab s BSB

More information

NEW IHC A n t i b o d i e s

NEW IHC A n t i b o d i e s NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology

More information

Conflict of interest. Gynecologic Pathology. Gynecologic Pathology

Conflict of interest. Gynecologic Pathology. Gynecologic Pathology The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix, vagina and vulva Conflict of interest None (but the ovary is my favorite organ) Ålborg, June 10, 2015 Prof. Ben

More information

Cleveland Clinic Laboratories

Cleveland Clinic Laboratories Cleveland Clinic Laboratories Anatomic Pathology Special Stains Group I for Microorganisms Special Stains Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram PAS/light green counterstain Warthin-Starry

More information

International Catalogue 2016/2017

International Catalogue 2016/2017 Detection Cell Control Arrays Accessory Reagents International Catalogue 2016/2017 Immunohistochemistry Selected Reagents for Diagnostics and Research Content Antibodies Positive control list for primary

More information

DOUBLE STAINS. Toll-Free: Direct:

DOUBLE STAINS. Toll-Free: Direct: DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml

More information

IIImmunohistochemistry (IHC) Outreach Services

IIImmunohistochemistry (IHC) Outreach Services IIImmunohistochemistry (IHC) Outreach Services Note type of fixative used if not neutral buffered formalin. Note type of tissue/specimen Unless specified otherwise, positive and negative controls react

More information

Differential diagnosis of HCC

Differential diagnosis of HCC Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis

More information

Your single-source laboratory solution. Antibody Library

Your single-source laboratory solution. Antibody Library Your single-source laboratory solution. Antibody Library A-ACT Alpha-1 antichymotrypsin; histiocytes; pancreatic pseudopapillary tumor A-AT Alpha-1-antitrypsin; inherited AAT deficiency ACTH Adrenocorticotropic

More information

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review

Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana

More information

Reporting of carcinoma of unknown primary tumour (CUP)

Reporting of carcinoma of unknown primary tumour (CUP) Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets

More information

Diagnostic IHC of endocrine, renal, prostate and germ cell tumor pathology

Diagnostic IHC of endocrine, renal, prostate and germ cell tumor pathology Diagnostic IHC of endocrine, renal, prostate and germ cell tumor pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Markers for endocrine

More information

Zytomed Systems GmbH

Zytomed Systems GmbH Zytomed Systems GmbH Anhaltiner Straße 16 14163 Berlin hone +49 30 80 49 84 990 Fax +49 30 80 49 84 999 international@zytomed-systems.de www.zytomed-systems.com 2 Content ositive control list for primary

More information

Advanced Staining Catalog

Advanced Staining Catalog Advanced Staining Catalog Novocastra TM IHC Antibodies, Probes & Leica BOND Reagents 2014 USA Edition Pathologists see the difference Over 20 Years of Expertise: Trust our IHC and ISH solutions to deliver

More information

CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY

CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate

More information

immunohistochemistry stain offerings

immunohistochemistry stain offerings immunohistochemistry stain offerings TRUSTED PATHOLOGISTS. INVALUABLE ANSWERS. www.aruplab.com/ap-ihc OCTOBER MARCH 2017 Information in in this brochure is is current as as of of October March 2017. All

More information

THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB

THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB CHARACTERISTIC OF THE IDEAL TUMOR MARKER Specific Sensitive Easy to perform Easy to interpret Adaptable to FNA Reasonable cost (CHEAP) THYROID TUMOR MARKERS

More information

New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape.

New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape. New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape Table of Contents I. Introduction II. Major Product Development Opportunities A.

More information

New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape. Table of Contents

New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape. Table of Contents New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape I. Introduction II. Worldwide Market Overview Table of Contents 1. Market Overview 2. Worldwide Market

More information

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment Reprinted by permission of UK NEQAS Immunocytochemistry and David S. Gray Kind thanks to David S. Gray for allowing ThermoFisher Scientific, Lab Vision Products, to distribute this article. Immunocytochemistry

More information

Liver cancer and normal cell lines

Liver cancer and normal cell lines The Essentials of Life Science Research Globally Deed Liver cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed HTB-79 Capan-1 pancreas: adenocarcinoma

More information

Carcinoma of unknown primary origin (CUP) is defined

Carcinoma of unknown primary origin (CUP) is defined REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin

More information

This article attempts to avoid the repeating of prior organ-specific

This article attempts to avoid the repeating of prior organ-specific Application of Immunohistochemistry to Cytology Larry J. Fowler, MD; Whitney A. Lachar, MD Context. The uses of monoclonal antibodies via immunochemistry have been reported frequently within the literature

More information

Receptors Functions and Signal Transduction L1- L2

Receptors Functions and Signal Transduction L1- L2 Receptors Functions and Signal Transduction L1- L2 Faisal I. Mohammed, MD, PhD University of Jordan 1 Introduction to Physiology (0501110) Spring 2013 Subject Receptors: types and adaptation - Membrane

More information

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors. Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer

More information

Diagnostic BioSystems

Diagnostic BioSystems Diagnostic BioSystems 2013-2014 Anatomic Pathology Catalog Histology and Advanced IHC Staining Products Ordering Information Orders: Orders will be accepted via phone, fax, mail or e-mail. Toll Free: (888)

More information

3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships

3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS Jason L. Hornick, M.D., Ph.D. Director of Surgical Pathology and Immunohistochemistry Brigham and Women s Hospital Professor

More information

Basic tumor nomenclature

Basic tumor nomenclature Jonas Nilsson jonas.a.nilsson@surgery.gu.se Sahlgrenska Cancer Center Bilder gjorda av Per Holmfeldt och Jonas Nilsson Benign tumor Basic tumor nomenclature Malignant tumor = cancer Metastasis Carcinoma:

More information

Classification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases

Classification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases Immunohistochemical classification of haematolymphoid tumours Haematolymphoid Neoplasias: Leukaemia vs Lymphoma C L O N A L M A L I G N A N C I E S Stephen Hamilton-Dutoit Institute of Pathology Aarhus

More information

PRODUCT LIST 2018 Immunoassays RIA, IRMA, REA

PRODUCT LIST 2018 Immunoassays RIA, IRMA, REA PRODUCT LIST 2018 Immunoassays RIA, IRMA, REA REPRODUCTIVE - FERTILITY REPRODUCTIVE ANDROGENS Androstanediol glucuronide DSL9200 RIA CT 100 185 Androstenedione IM0674 RIA CT 100 185 Androstenedione DSL3800

More information

Types of target values, acceptable ranges

Types of target values, acceptable ranges Types of target values, acceptable ranges As the differential of rounding, maximum 1 percent point deviation is allowed from the maximum acceptable range. 100. Clinical chemistry (wet) 1. Calcium RMV 10

More information

Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami

Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami Ascitic Fluid and Use of Immunocytochemistry Mercè Jordà, University of Miami Is It Malignant? Yes? No Ascitic Fluid Cytomorphologic Useful Findings Tight clusters with smooth borders Cellular and nuclear

More information

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452

More information

Non-Hodgkin s Lymphomas Version

Non-Hodgkin s Lymphomas Version NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell

More information

R.G.C.C.-RESEARCH GENETIC CANCER CENTRE LTD

R.G.C.C.-RESEARCH GENETIC CANCER CENTRE LTD ONCONOMICS 1 / 13 R.G.C.C.-RESEARCH GENETIC CANCER CENTRE LTD Dear colleague, Florina, / / We send you the results from the analysis on a patient suffering from carcinoma stage. The sample that was sent

More information

Immunohistochemistry on Limited Tissue Samples: Do s and Don ts

Immunohistochemistry on Limited Tissue Samples: Do s and Don ts Disclosures Immunohistochemistry on Limited Tissue Samples: Do s and Don ts I fretted over this... Andrew M Bellizzi, M.D. Department of Pathology University of Iowa Hospitals and Clinics andrew bellizzi@uiowa.edu

More information

Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma?

Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma? Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma? skin Jane L. Messina, MD Interna0onal Melanoma Pathology Working Group 4 th annual mee0ng Tampa, Florida November 14, 2011

More information

New Horizons in radionuclide therapy. John Buscombe Royal Free Hospital

New Horizons in radionuclide therapy. John Buscombe Royal Free Hospital New Horizons in radionuclide therapy John Buscombe Royal Free Hospital Date for you diary Interested in Radionuclide imaging and therapy using antibodies and peptides IRIST 2008 Krakow Poland 18-21 June

More information

Spindle Cell CA SPINDLE CELL LESIONS OF THE BREAST. Mammary Spindle Cell Lesions 04/13/2017

Spindle Cell CA SPINDLE CELL LESIONS OF THE BREAST. Mammary Spindle Cell Lesions 04/13/2017 Melinda F. Lerwill, MD Massachusetts General Hospital Harvard Medical School SPINDLE CELL LESIONS OF THE BREAST Mammary Spindle Cell Lesions Spindle cell carcinoma Fibromatosis Nodular fasciitis PASH Myofibroblastoma

More information

FNA Cytology of Metastatic Malignancies of Unknown Primary Site

FNA Cytology of Metastatic Malignancies of Unknown Primary Site FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Jan F. Silverman Pathologic Diagnosis of Metastasis Smaller specimens, less invasive techniques FNA cytology is highly

More information

FNA Cytology of Metastatic Malignancies of Unknown Primary Site

FNA Cytology of Metastatic Malignancies of Unknown Primary Site FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Cleveland Clinic Jan F. Silverman Alleghany Hospitals Pathologic Diagnosis of Metastasis Smaller specimens, less invasive

More information

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,

More information

GUNA -ACTH GUNA -BETA-ENDORFIN GUNA -BETA-ESTRADIOL ADRENOCORTICOTROPIC HORMONE

GUNA -ACTH GUNA -BETA-ENDORFIN GUNA -BETA-ESTRADIOL ADRENOCORTICOTROPIC HORMONE GUNA -ACTH Stimulation of the adrenal cortex hormones as follows: Glucocorticoids: hydrocortisone, corticosterone, cortisol Mineralcorticoids: aldosterone, 11-Deoxycorticosterone Sex hormones Asthenia

More information

Single and Multiplex Immunohistochemistry

Single and Multiplex Immunohistochemistry Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch

More information

Malignant neoplasms of the gastrointestinal (GI) tract,

Malignant neoplasms of the gastrointestinal (GI) tract, Special Section First Chinese American Pathologists Association Diagnostic Pathology Course, Part II Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary

More information

Minimum Whole Blood Volumes for Microcollection Tubes for Neonates, Pediatrics, Patients less than 45 kg (100 lb) and Difficult Collections

Minimum Whole Blood Volumes for Microcollection Tubes for Neonates, Pediatrics, Patients less than 45 kg (100 lb) and Difficult Collections The following table outlines the minimum whole blood volume that must be drawn into a microcollection tube (unless otherwise stated) for an individual test on a neonate, pediatric, patient weighing less

More information

Small Round Cell Tumors in Soft Tissue and Bone. ACCME/Disclosure. Adult Small Round Cell Tumors. Ewing Sarcoma 4/13/2016

Small Round Cell Tumors in Soft Tissue and Bone. ACCME/Disclosure. Adult Small Round Cell Tumors. Ewing Sarcoma 4/13/2016 Ultrastructural Pathology Society, Seattle, March, 2016 Small Round Cell Tumors in Soft Tissue and Bone ACCME/Disclosure Dr. Fisher has nothing to disclose Cyril Fisher MA MD DSc FRCPath Professor of Tumor

More information

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly

More information

BÁO GIÁ HÓA CHẤT MIỄN DỊCH

BÁO GIÁ HÓA CHẤT MIỄN DỊCH CÔNG TY TNHH ĐẦU TƯ & PHÁT TRIỂN KIM HƯNG Trụ sở chính Chi Nhánh 86 Lê Duẩn-Hoàn Kiếm-Hà Nội P 1801,Tầng 18, VSBC Tower,383B Cộng Hòa,Q Tân Bình-HCM Tel /Fax : 04. 3941 3887 Tel/Fax : 08. 6292 6913 Mobile

More information

Endocrinology - Reproduction Introduction Mohammed Y. Kalimi, Ph.D.

Endocrinology - Reproduction Introduction Mohammed Y. Kalimi, Ph.D. Endocrinology - Reproduction Introduction Mohammed Y. Kalimi, Ph.D. Objectives: After studying this material, the student will: 1. Identify the chemical nature of thyroid hormones, TRH, TSH, GH, somatoatatin,

More information

Genome Control in Cell Identity and Disease! Development and cell identity Loss of cell identity and disease New diagnostics and therapeutics

Genome Control in Cell Identity and Disease! Development and cell identity Loss of cell identity and disease New diagnostics and therapeutics Genome Control in Cell Identity and Disease! Development and cell identity Loss of cell identity and disease New diagnostics and therapeutics Development and cell identity! 30,000,000,000 cells!! Control

More information

Immunohistochemistry of the Skin

Immunohistochemistry of the Skin CE update [immunology histology chemistry] Immunohistochemistry of the Skin David Tacha, HT(ASCP)HTL, PhD BIOCARE Medical, Walnut Creek, CA DOI: 10.1309/PDPM26E5TLFQLUNG After reading this article the

More information

SCOPE OF ACCREDITATION TO ISO/IEC 17043:2010

SCOPE OF ACCREDITATION TO ISO/IEC 17043:2010 SCOPE OF ACCREDITATION TO ISO/IEC 17043:2010 BIO-RAD LABORATORIES 9500 Jeronimo Road Irvine, CA 92618-2017 Regulatory Phone (Elizabeth Platt): 949 598-1285 US Product Info/Sales: Phone: (800) 224-6723,

More information

Chapter 18: Endocrine Glands

Chapter 18: Endocrine Glands Chapter 18: Endocrine Glands I. Functions of the Endocrine System A. List and describe the eight major functions of the endocrine system: 1. 2. 3. 4. 5. 6. 7. 8. Page 1 of 19 C II. Pituitary Gland and

More information

The Endocrine System. Lab Exercise 31. Objectives. Introduction

The Endocrine System. Lab Exercise 31. Objectives. Introduction Lab Exercise The Endocrine System Objectives - Become familiar with the major endocrine glands and their location. - Learn some of the hormones produced by each gland. - Become familiar with the anatomy

More information

Optimization of antibodies, selection, protocols and controls Breast tumours

Optimization of antibodies, selection, protocols and controls Breast tumours Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin

More information

Hormones and Cancer Research Unit Department of Medicine, McGill University Dr. Jean-Jacques Lebrun

Hormones and Cancer Research Unit Department of Medicine, McGill University  Dr. Jean-Jacques Lebrun Hormones and Cancer Research Unit Department of Medicine, McGill University www.hcru.mcgill.ca Dr. Jean-Jacques Lebrun TGF /Smad signaling pathways CELLULAR AND MOLECULAR BIOLOGY Institut de recherches

More information

Biopsy Interpretation of Spindle cell proliferations of the Serosa

Biopsy Interpretation of Spindle cell proliferations of the Serosa Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)

More information

Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D.

Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D. Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D. I. Growth Hormone (somatotropin): Growth hormone (GH) is a 191 amino acid single chain polypeptide (MW 22,000 daltons). Growth

More information

CHAPTER 41: Animal Hormones

CHAPTER 41: Animal Hormones CHAPTER 41: Animal Hormones 1. List a few similarities and differences comparing: a. endocrine system b. nervous system 2. What is the difference between endocrine and exocrine glands? 3. What is the difference

More information

The Role of Liquid-Based Cytology and Ancillary Techniques in Pleural and Pericardic Effusions: An Institutional Experience

The Role of Liquid-Based Cytology and Ancillary Techniques in Pleural and Pericardic Effusions: An Institutional Experience The Role of Liquid-Based Cytology and Ancillary Techniques in Pleural and Pericardic Effusions: An Institutional Experience Esther Diana Rossi, MD, PhD, MIAC 1 ; Tommaso Bizzarro, BD 1 ; Fernando Schmitt,

More information

Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS. External Quality Assurance Services

Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS. External Quality Assurance Services Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS External Quality Assurance Services Table of Contents About Bio-Rad EQAS EQAS Program Overview.... 3 Online EQAS Resources... 4 Submitting

More information

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte

More information

Endocrine Histology Lab GUIDE TO MICROSCOPES IN LAB

Endocrine Histology Lab GUIDE TO MICROSCOPES IN LAB Endocrine Histology Lab GUIDE TO MICROSCOPES IN LAB The micrographs that appear on this review page are typical views of the tissues seen in the laboratory. The descriptions that accompany them are designed

More information

Trophoblastic tumors

Trophoblastic tumors Trophoblastic tumors Uterus tumor course Oslo, 21-22/1/16 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Cases 45 38 39 4 Case 45

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Spontaneous. Tumour induction. Immunosuppression

Spontaneous. Tumour induction. Immunosuppression Tumor immunology is the study of : 1- The antigenic properties of the tumor cells 2- The host IR to these tumor cell 3- The immunologic consequences to the host of the growth of the malignant cells 4-

More information

Supplemental Information. High-Throughput Microfluidic Labyrinth for the. Label-free Isolation of Circulating Tumor Cells

Supplemental Information. High-Throughput Microfluidic Labyrinth for the. Label-free Isolation of Circulating Tumor Cells Cell Systems, Volume 5 Supplemental Information High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells Eric Lin, Lianette Rivera-Báez, Shamileh Fouladdel, Hyeun

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

Genetic Studies of Dysgerminoma

Genetic Studies of Dysgerminoma Genetic Studies of Chromosome 12p abnormalities are characteristic of germ cell tumors isochromosome 12p and 12p overrepresentation Some can be detected by karyotyping FISH study of 21 dysgerminomas showed

More information

Uncommon secondary tumour of the stomach

Uncommon secondary tumour of the stomach Uncommon secondary tumour of the stomach B. Bancel, Hôpital CROIX ROUSSE LYON Bucharest Nov 2013 Case report 33-year old man Profound mental retardation and motor disturbances (sequelae of neonatal meningeal

More information

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC

More information

Cancer of Unknown Primary Sites: What Radiologists Need to Know and What Oncologists Want to Know

Cancer of Unknown Primary Sites: What Radiologists Need to Know and What Oncologists Want to Know Special Articles Review Kim et al. Cancer of Unknown Primary Sites Special Articles Review Kyung Won Kim 1,2 Katherine M. Krajewski 1 Jyothi P. Jagannathan 1 Mizuki Nishino 1 Atul B. Shinagare 1 Jason

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor

More information

RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS?

RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS? RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS? John C. Cheville, M.D. Mayo Clinic and Mayo Foundation Rochester, MN The majority of renal epithelial neoplasms are diagnosed on

More information

SwissProt/ TrEmbl Acc. No. 1 Description. Found in Other Studies 5. MW (kda) 2 pi 3 Function 4

SwissProt/ TrEmbl Acc. No. 1 Description. Found in Other Studies 5. MW (kda) 2 pi 3 Function 4 P02774 Vitamin D-binding protein precursor 52.95 5.4 Cell communication c, a,b S,C P08833 Insulin-like growth factor binding protein 1 precursor 27.88 5.1 Cell communication c, a P02760 AMBP protein precursor

More information

1. To describe the gross structure of the pituitary gland and be able to identify the pars nervosa, pars intermedia and pars distalis.

1. To describe the gross structure of the pituitary gland and be able to identify the pars nervosa, pars intermedia and pars distalis. ENDOCRINE Objectives 1. To describe the gross structure of the pituitary gland and be able to identify the pars nervosa, pars intermedia and pars distalis. 2. Identify and describe the histological features

More information

Immunotherapy Therapy for Prostate Cancer

Immunotherapy Therapy for Prostate Cancer 2006 Prostate Health Education Network African American Prostate Cancer Disparity Summit Immunotherapy Therapy for Prostate Cancer Glen W. McWilliams, MD Chief of Urology James J. Peters VAMC Assistant

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

Enterprise Interest None

Enterprise Interest None Enterprise Interest None What are triple negative breast cancers? A synopsis of their histological patterns Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology,

More information

Cutaneous amelanotic signet-ring cell malignant melanoma with interspersed myofibroblastic differentiation in a young cat

Cutaneous amelanotic signet-ring cell malignant melanoma with interspersed myofibroblastic differentiation in a young cat 644768VDIXXX10.1177/1040638716644768Signet-ring cell melanoma and myofibroblastic differentiationhirz, Herden research-article2016 Brief Communication Cutaneous amelanotic signet-ring cell malignant melanoma

More information

Detection of the Circulating Tumor Cells in Cancer Patients

Detection of the Circulating Tumor Cells in Cancer Patients Detection of the Circulating Tumor Cells in Cancer Patients Athanasios Armakolas; Zacharoula Panteleakou; Adrianos Nezos; Aikaterini Tsouma; Maria Skondra; Peter Lembessis; Nikolaos Pissimissis; Michael

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

MADE IN KOREA. Advanced POCT. Automated 6 Channels. Automated Single Channel. POCT to Desktop. Our technology covers it all!

MADE IN KOREA. Advanced POCT. Automated 6 Channels. Automated Single Channel. POCT to Desktop. Our technology covers it all! MADE IN KOREA Advanced POCT Automated 6 Channels Automated Single Channel POCT to Desktop Our technology covers it all! Compact Desktop Immuno- Automated desktop 6 channels 2 bays Bay random access Run

More information

The endocrine system

The endocrine system The endocrine system Overview I. Pituitary II. Adrenals III. Pancreas IV. Thyroid V. Parathyroids VI. Ovaries, testis fenestrated capillaries are general structures http://www.ama-assn.org/ama/pub/category/7157.html

More information

PROFILES MENU. Page no. 9 Page no. 8 Page no. 7 Page no. 6 Page no. 5. Page no. 2. Page no. 4 Page no. 3

PROFILES MENU. Page no. 9 Page no. 8 Page no. 7 Page no. 6 Page no. 5. Page no. 2. Page no. 4 Page no. 3 Health Profiles PROFILES MENU Page no. 1 Page no. 2 Page no. 4 Page no. 3 1 Basic Metabolic Panel (BMP) 2 Liver Function Tests (LFT) 3 Comprehensive Metabolic Panel (CMP) 4 Lipid Profile 5 Chem 7 Panel

More information

Zyto-Facts Editorial. News for Pathology and Immunohistochemistry. +++ Newsflash +++ Newsflash +++

Zyto-Facts Editorial. News for Pathology and Immunohistochemistry. +++ Newsflash +++ Newsflash +++ Zyto-Facts 1-2016 News for Pathology and Immunohistochemistry Editorial The primary site of a tumor is not known in about 3 % to 5 % of all cancer diagnoses. Patients, whose primary site could be identified,

More information

Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS. External Quality Assurance Services

Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS. External Quality Assurance Services Bio-Rad Laboratories EXTERNAL QUALITY ASSURANCE SERVICES EQAS External Quality Assurance Services Table of Contents About Bio-Rad EQAS EQAS Program Overview.... 3 Online EQAS Resources... 4 Submitting

More information

Chapter 8.2 The Endocrine System

Chapter 8.2 The Endocrine System Major Endocrine Organs Hypothalamus Pineal Gland Pituitary Gland Thyroid Gland Thymus Gland Adrenal Glands Pancreas Ovaries (Female) Testis (Male) Chapter 8.2 The Endocrine System The endocrine system

More information

Dissecting the immune response to colorectal cancer. Edus H. Warren, MD, PhD Fred Hutchinson Cancer Research Center April 25, 2013

Dissecting the immune response to colorectal cancer. Edus H. Warren, MD, PhD Fred Hutchinson Cancer Research Center April 25, 2013 Dissecting the immune response to colorectal cancer Edus H. Warren, MD, PhD Fred Hutchinson Cancer Research Center April 25, 2013 Increasing evidence suggests that the immune system influences the natural

More information

PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA

PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA 1 A good H & E helps! ADENOCARCINOMA DIAGNOSTIC CRITERIA Relatively uniform proliferation

More information

The pathologic diagnosis of malignant mesothelioma

The pathologic diagnosis of malignant mesothelioma Review Articles Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group Aliya Noor Husain, MD; Thomas V.

More information

IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS

IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SOFT TISSUE TUMORS Nicolas de Saint Aubain Somerhausen Institut Jules Bordet / Hôpital Erasme nicolas.desaintaubain@synet.be ForPath 2005 1 I. Ancillary techniques

More information